article
4 December 2018 | By Stefan Duhr (CEO at NanoTemperTechnologies)
Inefficiencies in drug discovery are hard to ignore when despite ever-increasing investment in pharmaceutical research and development, the number of new drugs approved by the US Food and Drug Administration (FDA) remains low.